Oral vaccination through voluntary consumption of the convict grouper Epinephelus septemfasciatus with yeast producing the capsid protein of red-spotted grouper nervous necrosis virus
Oral vaccination through voluntary consumption of the convict grouper Epinephelus septemfasciatus with yeast producing the capsid protein of red-spotted grouper nervous necrosis virus
复制标题
DOI：
10.1016/j.vetmic.2017.04.022
复制
发表时间：
2017-05-01
影响因子：
3.3
通讯作者：
Kim, Hong-Jin
中科院分区：
文献类型：
--
作者：
Cho, Seo Young;Kim, Hyoung Jin;Kim, Hong-Jin
神经坏死病毒（NNV）在海水养殖中造成严重的经济损失。红斑石斑鱼NNV（RGNNV）是世界上最常见的NNV物种。已经进行了许多努力来开发预防性NNV疫苗，并且已经提出了各种类型的疫苗候选物。然而，大多数疫苗被设计为注射疫苗，不适合大规模接种，对鱼类造成太大的压力。通过自愿喂食口服疫苗是为鱼类提供保护性免疫的理想方法。本研究利用重组酿酒酵母生产的RGNNV衣壳蛋白作为口服疫苗。重组酵母在破碎后以冷冻干燥形式制备。定罪石斑鱼分为三组，对照组，口服和胃肠外疫苗接种组，每组700条鱼。对照组未接受治疗，胃肠外组接受一次RGNNV病毒样颗粒的腹膜内注射，口服疫苗组食用含有裂解重组酵母的饲料;允许以一周的间隔自愿摄入四次。两个疫苗接种组均产生> 10（3）（log 2，9.96）的血清RGNNV中和抗体滴度，持续免疫后至少95天。此外，响应于用RGNNV的攻击，两组都遭受显著降低的死亡率，并且具有降低的脑RGNNV滴度。这些结果表明，重组酵母为基础的口服鱼疫苗有很大的潜力，大规模的疫苗接种。
Nervous necrosis viruses (NNV) cause serious economic losses in marine fish cultivation. The red-spotted grouper NNV (RGNNV) is the most common species of NNV worldwide. There have been many efforts to develop prophylactic NNV vaccines, and various types of vaccine candidate have been suggested. However, most were designed as injectable vaccines, which are not suitable for large-scale vaccination and cause too much stress to the fish. Oral vaccination through voluntary feeding is an ideal way to provide protective immunity to fish. In the present study, recombinant Saccharomyces cerevisiae producing RGNNV capsid protein was used as oral vaccine. The recombinant yeast was prepared in freeze-dried form after disruption. Convict groupers were divided into three groups, control, and oral and parenteral vaccination groups, each consisting of 700 fishes. The control group received no treatment, the parenteral group received one intraperitoneal injection of RGNNV virus-like particles, and the oral vaccination group consumed feed containing the lysed recombinant yeast; voluntary intake was allowed four times at one-week intervals. Both vaccination groups produced serum RGNNV neutralizing antibody titers of > 10(3) (log 2, 9.96), sustained for at least 95 days post-immunization. In addition, in response to challenge with RGNNV both groups suffered significantly reduced mortality and had reduced brain RGNNV titers. These results indicate that recombinant yeast-based oral fish vaccines have great potential for large-scale vaccination.